| At present the clinical treatment of prostate cancer | | | | tumor angiogenesis so that tumor tissue could not |
| is based on clinical staging, cell deterioration, and | | | | obtain the necessary blood, oxygen and other |
| patient circumstances, mainly surgery, radiation | | | | nutrients and ultimately "starving to death" in order to |
| therapy, hormonal therapy, chemotherapy, immune | | | | achieve the anti-cancer effect. Adverse reactions are |
| therapy and freezing treatment. | | | | hypertension, neutropenia, stomatitis, congestive |
| Below is the summary of prostate cancer cure | | | | heart failure, vomiting, and diarrhea. |
| tablets at present: | | | | 4 Immune therapy |
| 1.An androgen receptor blocker | | | | Dendreon's Provenge is developing a cancer |
| Androgen receptor antagonist is with endogenous | | | | immunotherapy drug that works by stimulating the |
| androgens in the target cells to compete with the | | | | patient's own immune system to fight prostate |
| combination of DHT receptors, inhibiting androgen into | | | | cancer. |
| the nucleus, with blocking its biological effects. | | | | 5 chemotherapy drugs |
| Androgen receptor blockers is with ease of use, | | | | Docetaxel by inhibiting cell division is necessary for |
| advantages, such as adverse reactions, which are | | | | tubulin and inhibit cancer cell division and proliferation |
| widely used in clinical practice. | | | | ,serveral years ago FDA was approved docetaxel |
| 2 LHRH analogues | | | | injection in combination with prednisone for the |
| LHRH analogues can suppress the release of pituitary | | | | treatment of advanced metastatic prostate cancer. |
| acting on the Leydig cells, inhibition of luteinizing | | | | 6 Other prostate cancer cure tablets |
| hormone and testosterone production, so that the | | | | Calcitriol is the natural form of vitamin D, which is in |
| blood fell to castration levels of testosterone. | | | | the body to play through the generation of hydroxyl |
| 3 vascular endothelial growth factor (VEGF) inhibitors, | | | | biological effects of chemotherapy drugs,which can |
| Bevacizumab is a VEGF inhibitor, mainly through the | | | | increase the anti-tumor activity of the specific |
| mechanism of action and in VEGF, with blocking it and | | | | mechanism of action is unknown. Common adverse |
| in the endothelial cell surface receptors. It can reduce | | | | reactions are mainly neutropenia, and fatigue. |